Document is current
Any future updates will be listed below
-
Authors
Kirk, Megan
Kwon, Joseph
Mavromati, Kalliopi
Gordon-Boyle, Adam
Bhui, Kamaldeep
Koychev, Ivan
Bauermeister, Sarah
Tsiachristas, Apostolos
-
Funding
Funding for this research was provided by:
NIHR Oxford Health Biomedical Research Centre
National Institute for Health and Care Research Applied Research Collaboration Oxford and Thames Valley
- License Information
-
More Information
Article History
Received: 5 October 2025
Accepted: 1 June 2026
First Online: 18 June 2026
Declarations
:
: Not applicable.
: This study was a secondary analysis of the Bio-Hermes001 dataset, a cross-sectional observational study where informed consent was previously obtained by all study participants prior to enrolment. ADDI provided consent to conduct the secondary analyses outlined in this study, no additional consent by participants was necessary.
: IK declares fees for advisory roles for Johnson and Johnson, Argenx, Novo Nordisk and companies in the field of dementia (CFDX Ltd (blood biomarkers), Five Lives SAS (digital interventions) and Paloma Health (remote dementia assessments)). IK owns shares in Five Lives SAS, CFDX Ltd and Paloma Health. No other conflicts to declare.
